Medicines planning

Preparing to use natalizumab biosimilar

6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.

Good governance when implementing natalizumab biosimilar

6 February 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.

The licence and supporting evidence for natalizumab biosimilar

6 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.

Considerations for developing national PGD templates

3 January 2024Decisions to develop PGD templates under the national Medicines Governance Do Once Programme depend on a variety of factors and advice on exclusions is given.

Understanding Patient Group Directions and Integrated Care Boards

3 May 2023We outline the responsibilities of ICBs in England as commissioners of NHS services using PGDs, and link to resources that provide further support and advice.

PGD use in Hospital at Home services, including Virtual Wards

28 March 2023Considerations required before implementing Patient Group Direction (PGDs) in Hospital at Home, including virtual ward, services

New Medicines News

5 January 2023

Registration required

Annual medicines planning publication, Prescribing Outlook

28 October 2022Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.

Costing Clinical Trials of ATIMPs using the NIHR iCT - Advice for Pharmacy Sites

12 July 2022Guidance to support and promote consistent pharmacy costing for commercial clinical trials involving ATIMPs.

Preparing to use ranibizumab biosimilar

29 June 2022Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team

SPS - Specialist Pharmacy Service

NHS